Literature DB >> 8382323

Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response.

Y Yanagihara1, M Kiniwa, K Ikizawa, T Shida, N Matsuura, A Koda.   

Abstract

The ability of IPD-1151T to suppress the induction of human IgE synthesis was investigated with an in vitro model of IgE production mediated by an allergen-specific helper T cell line (SN-4) from a patient allergic to Japanese cedar pollen. IPD-1151T induced a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis. In addition, the production of interleukin 4 (IL-4) by Cry j 1-activated SN-4 as well as that by phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) of normal donors was inhibited in a concentration-dependent manner by the agent. Interestingly, IPD-1151T clearly depressed PHA-induced expression of IL-4 mRNA in normal PBMC, indicating that this agent inhibits IL-4 gene transcription. However, IPD-1151T had no antagonistic action on IL-4, since neither IL-4-induced expression of low-affinity IgE receptor (Fc epsilon RII/CD23) on normal B cells nor soluble Fc epsilon RII release from IL-4-stimulated B cells was affected by the agent. On the other hand, IPD-1151T had no effect on the production of interferon-gamma by both Cry j 1-stimulated SN-4 and anti-CD3 monoclonal antibody-activated T cells of normal donors. These results suggest that the selective suppression of IgE synthesis by IPD-1151T results from the inhibition of IL-4 production by T cells at the gene level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382323     DOI: 10.1254/jjp.61.31

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  4 in total

1.  A preliminary study of PEFR monitoring in patients with chronic cough.

Authors:  T Sano; H Ueda; H Bando
Journal:  Lung       Date:  2004       Impact factor: 2.584

2.  Usefulness of suplatast tosilate for chronic cough following lung cancer surgery.

Authors:  Hideaki Miyamoto; Yukinori Sakao; Motoki Sakuraba; Shiaki Oh; Nobumasa Takahashi; Yoshikazu Miyasaka; Tomoya Inagaki; Taku Akaboshi; Enjo Hata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

3.  Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids.

Authors:  T Sano; Y Nakamura; H Yanagawa; H Bando; A Nii; S Yoshida; S Sone
Journal:  Lung       Date:  2003       Impact factor: 2.584

4.  Case of eosinophilic cystitis treated with suplatast tosilate as maintenance therapy.

Authors:  Tateki Yoshino; Hiroyuki Moriyama
Journal:  Case Rep Urol       Date:  2012-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.